Shingles shot put to the test in older HIV patients
NCT ID NCT05575830
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if the vaccine triggers a strong immune response and is safe in this group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Shingrix (recombinant zoster vaccine)
- What this could lead to
- If successful, this could show that the Shingrix vaccine works well in older adults with HIV, helping prevent shingles in this group.
- What could go wrong
- This is a phase 4 study, so the vaccine is already approved. The main question is whether it works as well in people with HIV, but immune responses may be weaker, and side effects like injection-site reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 225 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2022
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 95 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For PLWH: * Be registered in the SHCS or in the ANRS CO3 Aquitaine Cohort * Age \>50 YOA * Time since cART initiation \> 10 years * Not already vaccinated with RZV * HIV viral load \<50 copies/ml (within 6 months from the last blood sampling) * Informed consent as documented by signature * (France) : Person affiliated with or beneficiary of the French social security scheme For aged/gender-matched controls * Age \>50 YOA * Not already vaccinated with RZV * Informed consent as documented by signature * (France) Not HIV infected * (France) Person affiliated with or beneficiary of the French social security scheme Exclusion Criteria: * Ongoing signs of febrile or non-febrile infection at the time of the first vaccination * Immunosuppression from the following: * Current malignant neoplasm; * primary immunodeficiency; * recent (\<2 years) solid or bone-marrow transplant or any transplant still requiring immunosuppressive therapy * Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \[an equivalent dose of prednisolone \>20 mg/day \> 3 months\], monoclonal antibodies, cytostatics, biological products, etc.) within 6 months before screening. * Administration of immunoglobulins or any blood products within 3 months preceding the first dose of vaccine or planned administration during the study period * Having received a vaccine in the last month or is expected to receive a vaccine in the next month * Having received a shingles vaccine within one year * Presented with herpes zoster in the previous year * Contra-indication to RZV * Hospitalized patients * Unable to provide informed consent or inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Participation in another study with investigational drug within the 30 days preceding and during the present study. * (France) Pregnant or breastfeeding woman * (France) Patient governed by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bern University Hospital (Inselspital)
Bern, Canton of Bern, 3010, Switzerland
-
CHU de Bordeaux - Hôpital Haut-Lévèque
Pessac, Gironde, 33604, France
-
Centre Hospitalier Universitaire Vaudoise (CHUV)
Lausanne, Canton of Vaud, 1011, Switzerland
-
Ente Ospedaliero Cantonale
Lugano, Canton Ticino, 6900, Switzerland
-
Hôpital Saint-André, CHU de Bordeaux
Bordeaux, Bordeaux, 33075, France
-
Kantonsspital
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin
Bordeaux, France, 33000, France
-
University Hospital Basel
Basel, Basel, 4031, Switzerland
-
University Hospital Zurich
Zurich, Canton of Zurich, 8091, Switzerland
-
University Hospitals of Geneva
Geneva, Canton of Geneva, 1205, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can remote counseling help people with HIV cut back on alcohol?
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Four weeks vs twelve weeks: can a shorter TB prevention course work?
- Can a phone app keep young people with HIV engaged in care?
- Massive Real-World database aims to map how chronic diseases interact
- How do HIV drugs behave when kidneys fail? study measures blood levels